Our portfolio, supported by our fully integrated platform, establishes Celltrion USA as an important player in the U.S. immunology market.” BY LEE JAE-LIM [[email protected]] ...

Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...

Chief Commercial Officer at Celltrion USA, in a statement. “Our goal is to provide safe and effective alternatives and ensure ...

Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, immunoglobulin E-mediated food allergy and chronic spontaneous urticaria.

Celltrion announced the commercial launch of STEQEYMA® (ustekinumab-stba), a biosimilar of Janssen’s STELARA® (ustekinumab), in the United States. As we previously reported, the biosimilar was ...

Chief Commercial Officer at Celltrion USA. "With this launch, we are expanding our immunology portfolio beyond TNF-alpha to include IL-12/23 inhibitors, offering more options for multiple ...

Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...

“We are implementing an aggressive marketing strategy from the very start to secure early market share,” said Kim Bon-joong, CEO of Celltrion USA. “With our expanding product ...